Category: News

Post

Iterum Therapeutics Reports Third Quarter 2020 Financial Results

NDA Filing Expected Q4 2020 DUBLIN, Ireland and CHICAGO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial...

November 16, 2020November 16, 2020by In News
Post

Nabriva Therapeutics to Participate in Upcoming Virtual Investor Conferences

DUBLIN, Ireland, Nov. 12, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that management will participate in two upcoming investor conferences in November. Management will host investor meetings during the Jefferies Virtual London Healthcare Conference...

November 12, 2020November 12, 2020by In News
Post

Cidara Therapeutics to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in two upcoming conferences: the Stifel 2020 Virtual Healthcare...

November 11, 2020November 11, 2020by In News
Post

Summit Announces Closing of Private Placement of $50 Million

Summit Therapeutics Inc.(“Summit” or the “Company”) Summit Announces Closing of Private Placement of $50 Million Cambridge, MA, November 6, 2020 – Summit (NASDAQ: SMMT) today announces that it has closed its previously announced private placement for a fundraising of  $50 million (the “Fundraising”) through the issuance and sale of shares of common stock to the...

Post

Summit Announces Closing of Private Placement of $50 Million

Summit Therapeutics Inc.(“Summit” or the “Company”) Summit Announces Closing of Private Placement of $50 Million Cambridge, MA, November 6, 2020 – Summit (NASDAQ: SMMT) today announces that it has closed its previously announced private placement for a fundraising of  $50 million (the “Fundraising”) through the issuance and sale of shares of common stock to the...

Post

Summit Announces Closing of Private Placement of $50 Million

Summit Therapeutics Inc.(“Summit” or the “Company”) Summit Announces Closing of Private Placement of $50 Million Cambridge, MA, November 6, 2020 – Summit (NASDAQ: SMMT) today announces that it has closed its previously announced private placement for a fundraising of  $50 million (the “Fundraising”) through the issuance and sale of shares of common stock to the...

Post

SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update

SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update In October, SCYNEXIS submitted a New Drug Application (NDA) for ibrexafungerp for the treatment of vulvovaginal candidiasis (VVC) with expected approval in mid-2021. SCYNEXIS estimates that there are over 15 million antifungal prescriptions written each year...

Post

Cidara Provides Corporate Update and Reports Third Quarter 2020 Financial Results

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended September 30, 2020, and provided an update on its corporate activities. “We continue...

Post

Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update

WALTHAM, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its third quarter 2020 financial results and provided a business update. “We made considerable progress during the quarter despite the sustained headwinds of the COVID-19...

Post

Nabriva Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

-Relaunch of Xenleta® and Sivextro® commenced in late September-   – Type A Meeting with FDA for Contepo™ held on October 30th – -Conference call today at 4:30 p.m. Eastern Time– DUBLIN, Ireland, Nov. 05, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective...